September 7, 2026

GSK plc (GSK) Stock Analysis: Exploring a 17.41% Potential Upside in the Dynamic Healthcare Sector

As one of the stalwarts in the healthcare sector, GSK plc (NYSE: GSK) presents an intriguing opportunity for investors looking to capitalize on the pharmaceutical industry. With a robust market..

Cencora, Inc. (COR) Stock Analysis: Robust Growth in Medical Distribution with an 11.59% Upside Potential

Cencora, Inc. (NYSE: COR), formerly known as AmerisourceBergen Corporation, stands as a formidable player in the healthcare sector, specifically within the medical distribution industry. With a robust market capitalization of..

Teva Pharmaceutical Industries (TEVA) Stock Analysis: A 14% Upside Potential Amidst Analyst Optimism

Teva Pharmaceutical Industries (NYSE: TEVA), a key player in the healthcare sector, continues to draw significant investor interest with its robust presence in the specialty and generic drug manufacturing industry...

Labcorp Holdings Inc. (LH) Stock Analysis: Exploring the 4.47% Potential Upside in the Healthcare Diagnostics Leader

Labcorp Holdings Inc. (NYSE: LH), a dominant force in the healthcare diagnostics and research sector, stands at a pivotal point with its current stock price at $326.89. With a market..

HCA Healthcare, Inc. (HCA) Stock Analysis: Balancing Growth and Stability with an 11.48% Upside

Investors eyeing the healthcare sector should take note of HCA Healthcare, Inc. (NYSE: HCA), a major player in the medical care facilities industry with a market capitalization of $87.68 billion...

Novartis AG (NVS): Investor Outlook on Healthcare Giant with Robust Free Cash Flow and High ROE

Novartis AG (NYSE: NVS), a Swiss-based healthcare titan, is a key player in the drug manufacturing industry, focusing on a diverse range of therapeutic areas including cardiovascular, oncology, and neuroscience...

McKesson Corporation (MCK) Stock Analysis: Valuation Insights and Growth Potential in Healthcare Distribution

McKesson Corporation (NYSE: MCK), a titan in the healthcare distribution sector, continues to exhibit remarkable resilience and growth potential despite a complex market landscape. With a current market capitalization of..

Veeva Systems Inc. (VEEV) Stock Analysis: Strong Buy Ratings Amid Robust Revenue Growth

Veeva Systems Inc. (NYSE: VEEV), a leader in cloud-based solutions tailored for the life sciences industry, presents a compelling investment opportunity. With a market capitalization of $44.54 billion, the company..

Thermo Fisher Scientific Inc. (TMO) Stock Analysis: A Leading Healthcare Giant with Strong Revenue Growth Prospects

Thermo Fisher Scientific Inc. (NYSE: TMO), a powerhouse in the healthcare sector, continues to capture the attention of investors with its robust market presence and influential role in the diagnostics..

Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 14.46% Upside in the Healthcare Giant

Eli Lilly and Company (NYSE: LLY) stands as a towering figure in the healthcare sector with a market capitalization of $1.02 trillion. This Indianapolis-based pharmaceutical giant, founded in 1876, continues..

Becton, Dickinson and Company (BDX) Stock Analysis: Exploring a 5.91% Potential Upside in the Healthcare Giant

Becton, Dickinson and Company (NYSE: BDX), a stalwart in the healthcare sector, is capturing investor attention with its substantial market cap of $50.32 billion and a strategic focus on innovation..

Medtronic plc (MDT) Stock Analysis: Unpacking a Potential 11.25% Upside in the Medical Device Sector

Medtronic plc (NYSE: MDT), a global leader in medical devices, offers a compelling investment opportunity for investors seeking exposure in the healthcare sector. With a market capitalization of $120.46 billion,..

Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Titan with 4.29% Upside and Robust Buy Ratings

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a formidable player in the biotechnology sector, showcasing a market capitalization of $138.42 billion. Known for its innovative approach in treating serious diseases,..

Haleon plc (HLN) Stock Analysis: Exploring a 24.94% Potential Upside in Healthcare Investment

Haleon plc (HLN), a prominent player in the healthcare sector, is capturing the attention of investors with its strong market presence and promising growth trajectory. With a market capitalization of..

Danaher Corporation (DHR) Investor Outlook: A Strong ‘Buy’ with a 10% Upside Potential

Danaher Corporation, trading under the ticker DHR on the New York Stock Exchange, stands as a titan in the healthcare sector, specifically within the diagnostics and research industry. With a..

Boston Scientific Corporation (BSX) Stock Analysis: Exploring the 31% Potential Upside

Boston Scientific Corporation (NYSE: BSX) stands as a titan in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $69.27 billion, the company continues to..

Ampeak Energy advances Uskmouth battery portfolio with £7.8m AW1 investment

Ampeak Energy has secured £7.8 million for its AW1 battery project as construction progresses and its larger AW2 development moves forward with planning approval...

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing..

Grainger reports strong rental demand and outlines FY29 growth plan

Grainger said occupancy remained high at 96% and like-for-like rental growth reached 3% as it reaffirmed plans to grow earnings by 35% from FY25 to FY29, reduce net debt and..

Standard Life H1 operating profit rises 25% as 2026 targets remain on track

Standard Life reported £563m of adjusted operating profit and £745m of operating cash generation in H1 2026, with all full-year targets on track...
Search

Funds

September 7, 2026

Ampeak Energy advances Uskmouth battery portfolio with £7.8m AW1 investment

Ampeak Energy has secured £7.8 million for its AW1 battery project as construction progresses and its larger AW2 development moves forward with planning approval...

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death...

Grainger reports strong rental demand and outlines FY29 growth plan

Grainger said occupancy remained high at 96% and like-for-like rental growth reached 3% as it reaffirmed plans to grow earnings by 35% from FY25 to FY29, reduce net debt and accelerate non-core asset disposals...

Standard Life H1 operating profit rises 25% as 2026 targets remain on track

Standard Life reported £563m of adjusted operating profit and £745m of operating cash generation in H1 2026, with all full-year targets on track...
Search

Funds

September 7, 2026

FTSE 100

Funds